EcoDrugPlus

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4

Ensembl ID : ENSMMMG00000018846
Gene Symbol: PSMD4
3 Cross references
282 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSMMMG00000020391
Gene Symbol: PSMC1
3 Cross references
175 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSMMMG00000015270
Gene Symbol: PSMC3
3 Cross references
226 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSMMMG00000020683
Gene Symbol: PSMC4
3 Cross references
197 Possible Orthologues:

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSMMMG00000010130
Gene Symbol: PSMC5
2 Cross references
225 Possible Orthologues:

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSMMMG00000001802
Gene Symbol: PSMC6
3 Cross references
234 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSMMMG00000001400
Gene Symbol: PSMD1
3 Cross references
210 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSMMMG00000013441
Gene Symbol: PSMD11
3 Cross references
283 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSMMMG00000011521
Gene Symbol: PSMD12
3 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSMMMG00000007306
Gene Symbol: PSMD13
3 Cross references
218 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 14

Ensembl ID : ENSMMMG00000022716
Gene Symbol: PSMD14
3 Cross references
211 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 3

Ensembl ID : ENSMMMG00000007551
Gene Symbol: PSMD3
3 Cross references
212 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).